Thyroid stunning in clinical practice: Is it a real problem?

M. Filesi, M. Colandrea, T. Montesano, R. D'Apollo, G. Ronga

Research output: Contribution to journalArticle

Abstract

Stunning is a phenomenon of reducing 131I uptaking activity by residual or metastatic tissue during the follow-up of patients after total thyroidectomy for differentiated thyroid carcinoma. It was observed at whole body scintigraphy performed after therapeutic dose, administered for remnant ablation, in patients who were previously given a 131I dose for diagnostic purpose. This phenomenon could influence the efficacy of radioisotopic therapy, making it unsuccessful. Stunning was observed also in case of hyperthyroidism treated by fractionated doses of 131I. After a careful revision of literature, Authors report their last 10 years-experience about very few cases of supposed stunning, observed in oncological and hyperthyroidal patients who underwent diagnostic scan and radioiodine therapy. In case of differentiated thyroid carcinoma, we recommended a careful selection of patients who will be given ablative therapy using very low diagnostic doses and administering further therapeutic dose in a short time. In case of hyperthyroidism treatment, it is confirmed the opportunity of a single therapeutic dose with TSH value within the normal range. Because it was found out a very small number of cases in our wide population, we conclude that stunning is not influent in clinical practice, above all if "well- practice" diagnostic-therapeutical procedures are strictly observed.

Original languageEnglish
Pages (from-to)29-36
Number of pages8
JournalMinerva Endocrinologica
Volume34
Issue number1
Publication statusPublished - Mar 2009

Fingerprint

Thyroid Gland
Hyperthyroidism
Thyroid Neoplasms
Therapeutics
Thyroidectomy
Radionuclide Imaging
Patient Selection
Reference Values
Population

Keywords

  • Physiology
  • Radiopharmaceuticals
  • Thyroid diseases
  • Thyroid neoplasms
  • Thyroidectomy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology
  • Medicine(all)

Cite this

Filesi, M., Colandrea, M., Montesano, T., D'Apollo, R., & Ronga, G. (2009). Thyroid stunning in clinical practice: Is it a real problem? Minerva Endocrinologica, 34(1), 29-36.

Thyroid stunning in clinical practice : Is it a real problem? / Filesi, M.; Colandrea, M.; Montesano, T.; D'Apollo, R.; Ronga, G.

In: Minerva Endocrinologica, Vol. 34, No. 1, 03.2009, p. 29-36.

Research output: Contribution to journalArticle

Filesi, M, Colandrea, M, Montesano, T, D'Apollo, R & Ronga, G 2009, 'Thyroid stunning in clinical practice: Is it a real problem?', Minerva Endocrinologica, vol. 34, no. 1, pp. 29-36.
Filesi M, Colandrea M, Montesano T, D'Apollo R, Ronga G. Thyroid stunning in clinical practice: Is it a real problem? Minerva Endocrinologica. 2009 Mar;34(1):29-36.
Filesi, M. ; Colandrea, M. ; Montesano, T. ; D'Apollo, R. ; Ronga, G. / Thyroid stunning in clinical practice : Is it a real problem?. In: Minerva Endocrinologica. 2009 ; Vol. 34, No. 1. pp. 29-36.
@article{519eef17d5ea4cda820b89998df322d8,
title = "Thyroid stunning in clinical practice: Is it a real problem?",
abstract = "Stunning is a phenomenon of reducing 131I uptaking activity by residual or metastatic tissue during the follow-up of patients after total thyroidectomy for differentiated thyroid carcinoma. It was observed at whole body scintigraphy performed after therapeutic dose, administered for remnant ablation, in patients who were previously given a 131I dose for diagnostic purpose. This phenomenon could influence the efficacy of radioisotopic therapy, making it unsuccessful. Stunning was observed also in case of hyperthyroidism treated by fractionated doses of 131I. After a careful revision of literature, Authors report their last 10 years-experience about very few cases of supposed stunning, observed in oncological and hyperthyroidal patients who underwent diagnostic scan and radioiodine therapy. In case of differentiated thyroid carcinoma, we recommended a careful selection of patients who will be given ablative therapy using very low diagnostic doses and administering further therapeutic dose in a short time. In case of hyperthyroidism treatment, it is confirmed the opportunity of a single therapeutic dose with TSH value within the normal range. Because it was found out a very small number of cases in our wide population, we conclude that stunning is not influent in clinical practice, above all if {"}well- practice{"} diagnostic-therapeutical procedures are strictly observed.",
keywords = "Physiology, Radiopharmaceuticals, Thyroid diseases, Thyroid neoplasms, Thyroidectomy",
author = "M. Filesi and M. Colandrea and T. Montesano and R. D'Apollo and G. Ronga",
year = "2009",
month = "3",
language = "English",
volume = "34",
pages = "29--36",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Thyroid stunning in clinical practice

T2 - Is it a real problem?

AU - Filesi, M.

AU - Colandrea, M.

AU - Montesano, T.

AU - D'Apollo, R.

AU - Ronga, G.

PY - 2009/3

Y1 - 2009/3

N2 - Stunning is a phenomenon of reducing 131I uptaking activity by residual or metastatic tissue during the follow-up of patients after total thyroidectomy for differentiated thyroid carcinoma. It was observed at whole body scintigraphy performed after therapeutic dose, administered for remnant ablation, in patients who were previously given a 131I dose for diagnostic purpose. This phenomenon could influence the efficacy of radioisotopic therapy, making it unsuccessful. Stunning was observed also in case of hyperthyroidism treated by fractionated doses of 131I. After a careful revision of literature, Authors report their last 10 years-experience about very few cases of supposed stunning, observed in oncological and hyperthyroidal patients who underwent diagnostic scan and radioiodine therapy. In case of differentiated thyroid carcinoma, we recommended a careful selection of patients who will be given ablative therapy using very low diagnostic doses and administering further therapeutic dose in a short time. In case of hyperthyroidism treatment, it is confirmed the opportunity of a single therapeutic dose with TSH value within the normal range. Because it was found out a very small number of cases in our wide population, we conclude that stunning is not influent in clinical practice, above all if "well- practice" diagnostic-therapeutical procedures are strictly observed.

AB - Stunning is a phenomenon of reducing 131I uptaking activity by residual or metastatic tissue during the follow-up of patients after total thyroidectomy for differentiated thyroid carcinoma. It was observed at whole body scintigraphy performed after therapeutic dose, administered for remnant ablation, in patients who were previously given a 131I dose for diagnostic purpose. This phenomenon could influence the efficacy of radioisotopic therapy, making it unsuccessful. Stunning was observed also in case of hyperthyroidism treated by fractionated doses of 131I. After a careful revision of literature, Authors report their last 10 years-experience about very few cases of supposed stunning, observed in oncological and hyperthyroidal patients who underwent diagnostic scan and radioiodine therapy. In case of differentiated thyroid carcinoma, we recommended a careful selection of patients who will be given ablative therapy using very low diagnostic doses and administering further therapeutic dose in a short time. In case of hyperthyroidism treatment, it is confirmed the opportunity of a single therapeutic dose with TSH value within the normal range. Because it was found out a very small number of cases in our wide population, we conclude that stunning is not influent in clinical practice, above all if "well- practice" diagnostic-therapeutical procedures are strictly observed.

KW - Physiology

KW - Radiopharmaceuticals

KW - Thyroid diseases

KW - Thyroid neoplasms

KW - Thyroidectomy

UR - http://www.scopus.com/inward/record.url?scp=67650345612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650345612&partnerID=8YFLogxK

M3 - Article

C2 - 19209126

AN - SCOPUS:67650345612

VL - 34

SP - 29

EP - 36

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 1

ER -